Mindshift Compounds News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public Compass Pathways (NASDAQ:CMPS) and MindMed (NASDAQ:MNMD) remain the only two companies in psychedelics to reach a major U.S. stock exchange. Both companies presented net losses associated with R&D expenses, as entities in the space race towards gaining ground in a sector that still hasn’t reached early maturity or profitability. Both companies presented strong cash positions to advance their research pipelines. Compass, Pressing On Psilocybin: Compass highlighted the issuing of two new ...

MindMed (NEO: MMED) (OTCQB: MMEDF) agreed to buy HealthMode

Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ -- Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics "psychiatry's brave new world." The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by le...

Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit.  The proceeds will be used to finance product research and development, advance the company’s technological capabilities, marketing expenditures and product awareness, as well as for working capital. So far, Mind Cure has raised almost CA$31 million ($24.4 million) to date. The company’s operations are divided betwee...